News

Health & Wellness Emerge as Wall Street’s Ultimate Strategic Asset, Reshaping Competitive Landscape with CourMed at the Forefront
A recent article published by Impact Wealth Magazine highlights a significant paradigm shift within the financial services industry: wellness is no longer a mere perk but has become the “ultimate ...
Biomednewsbreaks - Nanoviricides (NYSE American: NNVC) Reports Breakthrough Measles Drug Success In Humanized Animal Study
NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage developer of broad-spectrum antivirals using host-mimetic nanomedicine, announced promis ...
Royal LePage Terrequity Realty Wins 2025 Consumer Choice Award for Residential Real Estate in Toronto Central
TORONTO, ONTARIO / ACCESS Newswire / July 21, 2025 / Royal LePage Terrequity Realty has been honoured with the 2025 Consumer Choice Award in the Residential Real Estate category for Toronto Central, ...
Measles Now Has a Drug – NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...
Pharmabiz4d
NanoViricides designs trial protocol for phase II MPox Clade Ia with a novel drug NV-387 for treating MPox disease
Shelton, Connecticut Thursday, July 17, 2025, 18:00 Hrs [IST] ...
Biomednewsbreaks - Nanoviricides, Inc. (NYSE American: NNVC) Highlights Mpox Drug Progress As WHO Extends Global Health Emergency
NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage pioneer in host-mimetic nanomedicine, affirmed its preparedness to address the continued ...
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...